Guardant Health, Inc. (NASDAQ:GH) Receives $106.86 Consensus Target Price from Analysts

Guardant Health, Inc. (NASDAQ:GH) has received a consensus rating of “Moderate Buy” from the twenty-three brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and twenty-one have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $117.4286.

A number of research firms recently weighed in on GH. Canaccord Genuity Group boosted their price target on shares of Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday. Wells Fargo & Company boosted their target price on Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Friday. BTIG Research upped their price target on Guardant Health from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Friday. UBS Group reaffirmed a “buy” rating and issued a $175.00 price target on shares of Guardant Health in a report on Friday, January 30th. Finally, TD Cowen boosted their price objective on Guardant Health from $130.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday.

Insider Activity

In other Guardant Health news, CEO Helmy Eltoukhy sold 90,565 shares of the business’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $103.82, for a total value of $9,402,458.30. Following the transaction, the chief executive officer directly owned 2,047,143 shares in the company, valued at $212,534,386.26. The trade was a 4.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Michael Brian Bell sold 80,362 shares of the stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $103.14, for a total transaction of $8,288,536.68. Following the completion of the sale, the chief financial officer directly owned 28,052 shares of the company’s stock, valued at approximately $2,893,283.28. This trade represents a 74.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 434,511 shares of company stock worth $45,580,887. Insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Emerald Advisers LLC raised its holdings in Guardant Health by 24.8% in the 3rd quarter. Emerald Advisers LLC now owns 873,203 shares of the company’s stock valued at $54,558,000 after buying an additional 173,281 shares during the period. Knights of Columbus Asset Advisors LLC acquired a new stake in shares of Guardant Health during the third quarter valued at about $1,554,000. Edgestream Partners L.P. increased its position in shares of Guardant Health by 147.3% during the second quarter. Edgestream Partners L.P. now owns 50,519 shares of the company’s stock valued at $2,629,000 after acquiring an additional 30,094 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH raised its stake in shares of Guardant Health by 54.4% in the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 301,449 shares of the company’s stock valued at $18,835,000 after acquiring an additional 106,263 shares during the period. Finally, State of Wyoming acquired a new position in shares of Guardant Health in the 2nd quarter worth approximately $567,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

More Guardant Health News

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Multiple brokerages raised price targets and maintained buy/overweight ratings (Leerink to $180, JPMorgan to $130, Wells Fargo to $125, BTIG to $145, Canaccord to $135), signaling analyst confidence in upside from current levels. Analyst Raises Coverage
• Positive Sentiment: Q4 revenue beat and strong growth: Guardant reported $281.3M in Q4 revenue, +39% YoY and above consensus; management issued FY2026 revenue guidance around $1.3B, above Street expectations — a growth signal for core oncology testing. Press Release
• Positive Sentiment: Research coverage expansion: Robert W. Baird initiated coverage, which can broaden institutional interest and trading liquidity. Coverage Start
• Neutral Sentiment: Conference call and transcript available — provides detail on cadence of test volume, reimbursement progress and product roadmap; useful for digging into guidance assumptions. Earnings Transcript
• Neutral Sentiment: Market materials (slide deck, press release) posted for investors to verify segment trends and margin assumptions. Slide Deck / Press Release
• Neutral Sentiment: Short-interest data flagged a “significant increase” entry but shows 0 shares / NaN in the feed — the published data appears inconsistent, so short-interest impact is unclear. Short Interest Note
• Negative Sentiment: EPS miss: GAAP loss of ($0.50) vs. consensus (~($0.43)), which disappointed some investors despite revenue upside and may have pressured the stock near the close. Earnings Reaction
• Negative Sentiment: Management left EPS guidance effectively blank in the release (revenue guidance given but no numeric EPS target), which can create uncertainty around near-term profitability expectations. Guidance Details

Guardant Health Price Performance

Shares of NASDAQ:GH opened at $103.10 on Friday. Guardant Health has a 1 year low of $34.88 and a 1 year high of $120.74. The firm has a market capitalization of $12.99 billion, a PE ratio of -31.15 and a beta of 1.63. The business’s 50 day moving average price is $106.69 and its 200-day moving average price is $85.94.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The business had revenue of $281.27 million during the quarter, compared to the consensus estimate of $269.74 million. During the same quarter in the prior year, the firm earned ($0.62) EPS. The business’s quarterly revenue was up 39.4% compared to the same quarter last year. As a group, analysts expect that Guardant Health will post -2.9 earnings per share for the current year.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.